<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>House of Commons Inquiry</title></head><body><div><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written Evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">UK Blood Services Prion Working Group</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> (BTO0014)</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Background Information</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 50.65pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The background to </span><span style="font-family:'Times New Roman'; font-size:11pt">variant Creutzfeldt Jakob disease (v</span><span style="font-family:'Times New Roman'; font-size:11pt">CJD</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> has been appropriately put before the Committee by Dr Roland Salmon, Professor James Ironside and Professor Joh</span><span style="font-family:'Times New Roman'; font-size:11pt">n Collinge and it would not be appropriate to rei</span><span style="font-family:'Times New Roman'; font-size:11pt">terate their excellent summary here.</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 50.65pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">From the first descriptions of vCJD </span><span style="font-family:'Times New Roman'; font-size:11pt">there was concern amongst Blood Services </span><span style="font-family:'Times New Roman'; font-size:11pt">around the possibility that infection could be transmitted by blood - i</span><span style="font-family:'Times New Roman'; font-size:11pt">t was known to be a different strain of </span><span style="font-family:'Times New Roman'; font-size:11pt">prion </span><span style="font-family:'Times New Roman'; font-size:11pt">disease</span><span style="font-family:'Times New Roman'; font-size:11pt"> from sporadic CJD</span><span style="font-family:'Times New Roman'; font-size:11pt">, one </span><span style="font-family:'Times New Roman'; font-size:11pt">in </span><span style="font-family:'Times New Roman'; font-size:11pt">which individuals became infected through a peripheral </span><span style="font-family:'Times New Roman'; font-size:11pt">enteric route and one in which there </span><span style="font-family:'Times New Roman'; font-size:11pt">is</span><span style="font-family:'Times New Roman'; font-size:11pt"> demonstrable presence of abnormal prion protein in peripheral lymphoid tissue</span><span style="font-family:'Times New Roman'; font-size:11pt"> during </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">preclinical phase of infection</span><span style="font-family:'Times New Roman'; font-size:11pt">.  Thus a number of precautionary measures were taken at that stage including withdrawal and recall of blood compon</span><span style="font-family:'Times New Roman'; font-size:11pt">ents, plasma derivatives and </span><span style="font-family:'Times New Roman'; font-size:11pt">cellular tissues obtained from individual</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> who went on to develop vCJD </span><span style="font-family:'Times New Roman'; font-size:11pt">after donation </span><span style="font-family:'Times New Roman'; font-size:11pt">(announced December 1997), the importation of plasma from countries other than the UK for fractionation to manufacture plasma </span><span style="font-family:'Times New Roman'; font-size:11pt">products</span><span style="font-family:'Times New Roman'; font-size:11pt"> (announced May 1998</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">fully implemented October 1999)</span><span style="font-family:'Times New Roman'; font-size:11pt"> and leucodepletion of all blood components (decision announced July 1998</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> fully implemented </span><span style="font-family:'Times New Roman'; font-size:11pt">A</span><span style="font-family:'Times New Roman'; font-size:11pt">utumn 1999).</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 50.65pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In 1997 the Transfusion Medicine Epidemiology Review </span><span style="font-family:'Times New Roman'; font-size:11pt">(TMER) </span><span style="font-family:'Times New Roman'; font-size:11pt">was established as a collaboration between the National CJD Research and Surveillance Unit </span><span style="font-family:'Times New Roman'; font-size:11pt">(NCJDRSU) </span><span style="font-family:'Times New Roman'; font-size:11pt">and the UK Blood Services </span><a href="http://www.cjd.ed.ac.uk/TMER/results.htm"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">www.cjd.ed.ac.uk/TMER/results.htm</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> . Patients diagnosed with vCJD are notified to the UK Blood Services who investigate whether they have ever donated blood. Any recipients of blood components from those individuals are identified and NCJDRSU check whether these recipients have developed clinical vCJD. </span><span style="font-family:'Times New Roman'; font-size:11pt">If</span><span style="font-family:'Times New Roman'; font-size:11pt"> these people die, their death certificates are sent to NCJDRSU, and examined to determine whether there was any evidence of CJD contributing to the death.  Eighteen people who later developed vCJD have been traced as blood donors who gave blood donations that were transfused to recipients.  From these donors, 67 recipients of blood components have been identified, 15 of whom are still alive, all of whom have survived at least eight years since the blood transfusion.  These people and their doctors have been informed of their exposure to these blood components.</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 50.65pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In the reverse arm of the surveillance, patients who have developed vCJD are investigated to ascertain whether they were recipients of blood components before they developed vCJD. Ten patients with vCJD have been identified as having received blood components from a total of 209 donors, 192 of whom have been traced. In 3 of the 10 cases, it had already been established that one of the donors to that case had later developed vCJD. In the remaining cases, all the donors were excluded from further donation and </span><span style="font-family:'Times New Roman'; font-size:11pt">they remain under surveillance, </span><span style="font-family:'Times New Roman'; font-size:11pt">but no further cases of vCJD have been observed in the cohort of ex-donors. It remains uncertain, therefore, whether the 7 cases may represent transfusion-transmission, or are due to dietary exposure.</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 50.65pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In December 2003 the TMER reported the first presumed transmission of vCJD by blood transfusion.  The implicated red cell transfusion occurred in 1996. The blood donor was well at the time of blood donation but went on to develop symptoms of vCJD in 1999.  The recipient was diagnosed with vCJD in 2003.  A case of transmission of vCJD prions not leading to clinical disease was reported in July 2004.  On this occasion the patient received blood in 1999 from a donor who went on to develop symptoms of vCJD 18 months later.  The recipient died of unrelated causes five years after the transfusion with no evidence of neurological disease, but at post mortem examination was found to have evidence of abnormal prion accumulation in the spleen and the lymph nodes.  The second presumed blood transfusion associated transmission leading to clinical vCJD was reported in February 2006.  The patient developed symptoms about eight years after receiving a blood transfusion from a donor who developed symptoms of vCJD about 20 months after donating blood.  The third presumed blood associated transmission leading to clinical vCJD was reported in January 2007 in a patient who developed symptoms just over eight years after receiving a blood transfusion from a donor who</span><span style="font-family:'Times New Roman'; font-size:11pt">se</span><span style="font-family:'Times New Roman'; font-size:11pt"> symptoms of vCJD appeared around 17 months after donating blood.  These two </span><span style="font-family:'Times New Roman'; font-size:11pt">latter </span><span style="font-family:'Times New Roman'; font-size:11pt">cases were linked to a common donor. The presumed transmissions in these four cases therefore occurred from red cell transfusions between 1996 and 1999, before universal leucodepletion was introduced. In addition, the transfused red cell components proba</span><span style="font-family:'Times New Roman'; font-size:11pt">bly contained in the order of 35-40 </span><span style="font-family:'Times New Roman'; font-size:11pt">ml plasma, compared with current red cell preparations, which are prepared by removing all but 10-20ml of the plasma and resuspending the red cells  in an optimal additive solution. Thus, there are two differences between current red cell preparations and those in use when the transmission of abnormal prion protein occurred: universal leucodepletion and removal of </span><span style="font-family:'Times New Roman'; font-size:11pt">more</span><span style="font-family:'Times New Roman'; font-size:11pt"> of the plasma.</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 50.65pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In addition, 11 of the 18 identified blood donors contributed to 25 plasma pools from which 191 fractionated plasma products were manufactured, prior to the switch to </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">use </span><span style="font-family:'Times New Roman'; font-size:11pt">of </span><span style="font-family:'Times New Roman'; font-size:11pt">non-UK plasma for this purpose.  The CJD Incidents Panel developed a model for assessment of the level of risk of exposure of vCJD to recipients through such fractionated plasma products.  They calculated the dose of each product beyond which a 1% infection contr</span><span style="font-family:'Times New Roman'; font-size:11pt">ol threshold would be surpassed</span><span style="font-family:'Times New Roman'; font-size:11pt"> as discussed by Dr Salmon in his submission.  Patients who were identified as falling into this category were informed of their exposure and precautionary steps were taken to minimise the risk of any further transmission through blood, tissue or organ donation or by medical instrumentation.  Further information can be obtained from the Health Protection Agency: </span><a href="http://www.hpa.org.uk/topics/InfectiousDiseases/InfectionsAZ/CreutzfeldtJakobDisease/CJDIncidentsPanel/"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">www.hpa.org.uk/topics/InfectiousDiseases/InfectionsAZ/CreutzfeldtJakobDisease/CJDIncidentsPanel/</span></a><span style="font-family:'Times New Roman'; font-size:11pt">.  In 2009 a case of presumed transmission of abnormal prions was described in a patient with haemophilia who had received batches of factor VIII prepared from plasma pools including donations from a donor who subsequently died of vCJD.  The patient died of unrelated causes but was found at post mortem to have evidence of prion accumulation in his spleen.  It was unclear whether the presumed vCJD infection arose from transmission from the infected donor, transmission from another batch of </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> factor VIII or oral transmission through the food chain. </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 37.4pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 50.65pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Subsequent to </span><span style="font-family:'Times New Roman'; font-size:11pt">these</span><span style="font-family:'Times New Roman'; font-size:11pt"> description</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> of transmission of clinical vCJD by blood transfusion a series of further precautionary measures were </span><span style="font-family:'Times New Roman'; font-size:11pt">recommended by </span><span style="font-family:'Times New Roman'; font-size:11pt">the Committee on the Microbiological Safety of Blood, Tissues and Organs (MSBTO) and its successor, the </span><span style="font-family:'Times New Roman'; font-size:11pt">Advisory Committee on the Safety of Blood, Tissues and Organs </span><span style="font-family:'Times New Roman'; font-size:11pt">(SaBTO)</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 50.65pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Importation of clinical fresh frozen plasma (FFP) for patients born after January 1996, announced on 16</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt"> August 2003 and implemented by the end of June 2004.  This measure was extended to “all patients under the age of 16” by July 2005.  As those born on or after 1</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:'Times New Roman'; font-size:11pt"> January 1996 began to turn 17</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:11pt">from 1</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:'Times New Roman'; font-size:11pt"> January 2012 the treatment group was subsequently defined as all t</span><span style="font-family:'Times New Roman'; font-size:11pt">hose “born after January 1996”</span><span style="font-family:'Times New Roman'; font-size:11pt"> to ensure that individuals who are presumed unexposed through dietary means continued to receive imported plasma past their 17</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt"> birthday.</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 50.65pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Exclusion of whole blood donors who stated that they had received a blood component transfusion in the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> since 1</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:'Times New Roman'; font-size:11pt"> January 1980 (implemented April 2004).  Extended to whole blood and apheresis donors who may have received a blood component transfusion in the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> since 1</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:'Times New Roman'; font-size:11pt"> January 1980 (August 2004) and to any donors who have been treated with </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">plasma </span><span style="font-family:'Times New Roman'; font-size:11pt">derived </span><span style="font-family:'Times New Roman'; font-size:11pt">intravenous </span><span style="font-family:'Times New Roman'; font-size:11pt">immun</span><span style="font-family:'Times New Roman'; font-size:11pt">oglobulin or </span><span style="font-family:'Times New Roman'; font-size:11pt">undergone plasma exchange.  This </span><span style="font-family:'Times New Roman'; font-size:11pt">measure </span><span style="font-family:'Times New Roman'; font-size:11pt">was further extended in November 2005 to transfusions anywhere in the world.  The purpose of this excl</span><span style="font-family:'Times New Roman'; font-size:11pt">usion was to prevent tertiary and </span><span style="font-family:'Times New Roman'; font-size:11pt">higher order transmissions occurring through blood, tissue and organ transplantation and </span><span style="font-family:'Times New Roman'; font-size:11pt">thus </span><span style="font-family:'Times New Roman'; font-size:11pt">prolonging the outbreak in the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> population.</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Exclusion of blood donors whose blood had been transfused to recipients who later develop vCJD where transfusion cannot be excluded as the source of the vCJD infection </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt">no infected donor has been identified (July 2005).</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The UK Blood Services, Chief Medical Officer</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> and Departments of Health have pursued a </span><span style="font-family:'Times New Roman'; font-size:11pt">proactive</span><span style="font-family:'Times New Roman'; font-size:11pt"> Better Blood Transfusion programme seeking to improve the evidence base in relation to blood transfusion, and reduce inappropriate transfusion throug</span><span style="font-family:'Times New Roman'; font-size:11pt">h education and audit.  </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> Blood Services have seen a gradual </span><span style="font-family:'Times New Roman'; font-size:11pt">reduction</span><span style="font-family:'Times New Roman'; font-size:11pt"> in blood usage from </span><span style="font-family:'Times New Roman'; font-size:11pt">between</span><span style="font-family:'Times New Roman'; font-size:11pt"> 4</span><span style="font-family:'Times New Roman'; font-size:11pt">0-4</span><span style="font-family:'Times New Roman'; font-size:11pt">5 per 1000</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">of the population to</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">a</span><span style="font-family:'Times New Roman'; font-size:11pt"> current of 3</span><span style="font-family:'Times New Roman'; font-size:11pt">2-34</span><span style="font-family:'Times New Roman'; font-size:11pt"> per 1000 of the population</span><span style="font-family:'Times New Roman'; font-size:11pt">.  </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Following t</span><span style="font-family:'Times New Roman'; font-size:11pt">he inception of SaBTO </span><span style="font-family:'Times New Roman'; font-size:11pt">in 2008</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">further considerable work was undertaken to review all current blood transfusion vCJD safety measures in a systematic way.  The agenda and minutes and associated papers from SaBTO are available on-line (</span><a href="https://www.gov.uk/government/policy-advisory-groups/advisory-committee-on-the-safety-of-blood-tissues-and-organs"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/policy-advisory-groups/advisory-committee-on-the-safety-of-blood-tissues-and-organs</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> ) and in a</span><span style="font-family:'Times New Roman'; font-size:11pt">ddition we</span><span style="font-family:'Times New Roman'; font-size:11pt"> understand that SaBTO will be making a separate submission to the Committee which details this work.  </span><span style="font-family:'Times New Roman'; font-size:11pt">We</span><span style="font-family:'Times New Roman'; font-size:11pt"> will not therefore reiterate this here.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A number of different forms of tissues are transplanted, including</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">bone, </span><span style="font-family:'Times New Roman'; font-size:11pt">tendon, </span><span style="font-family:'Times New Roman'; font-size:11pt">heart valves, skin </span><span style="font-family:'Times New Roman'; font-size:11pt">and cornea.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">In addition, s</span><span style="font-family:'Times New Roman'; font-size:11pt">ome cellular products are routinely transplanted, such as haematopoietic stem cells from the bone marrow, peripheral blood or cord blood for patients </span><span style="font-family:'Times New Roman'; font-size:11pt">(so called bone marrow transplantation</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Finally, a variety of solid organs are transplanted including kidneys (from cadaveric and live donors), liver, pancreas, pancreatic islets, heart and lungs.  These organ transplants are often lifesaving or very significantly life-prolonging procedures.  </span><span style="font-family:'Times New Roman'; font-size:11pt">We will make a </span><span style="font-family:'Times New Roman'; font-size:11pt">separate submission covering </span><span style="font-family:'Times New Roman'; font-size:11pt">solid </span><span style="font-family:'Times New Roman'; font-size:11pt">organ</span><span style="font-family:'Times New Roman'; font-size:11pt"> transplantation.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Whilst there are some indicative data on the distribution of </span><span style="font-family:'Times New Roman'; font-size:11pt">tissue </span><span style="font-family:'Times New Roman'; font-size:11pt">infectivity in animal models of prion diseases, there are no good data on the level or distribution of vCJD infectivity in</span><span style="font-family:'Times New Roman'; font-size:11pt"> transplanted</span><span style="font-family:'Times New Roman'; font-size:11pt"> human</span><span style="font-family:'Times New Roman'; font-size:11pt"> cells, tissues and</span><span style="font-family:'Times New Roman'; font-size:11pt"> organs</span><span style="font-family:'Times New Roman'; font-size:11pt">. A risk assessment </span><span style="font-family:'Times New Roman'; font-size:11pt">w</span><span style="font-family:'Times New Roman'; font-size:11pt">as carried out which demonstrated that the mass of cells transplanted in these procedures was sufficiently large that a concentration of infectivity below that detectable by bioassay would suffice to transmit infection to a recipient. It was considered prudent therefore to consider all cell, tissue and organ transplants as potential routes for transmission of vCJD. </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 37.4pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A</span><span style="font-family:'Times New Roman'; font-size:11pt"> study h</span><span style="font-family:'Times New Roman'; font-size:11pt">as </span><span style="font-family:'Times New Roman'; font-size:11pt">been </span><span style="font-family:'Times New Roman'; font-size:11pt">conducted to assess whether patients </span><span style="font-family:'Times New Roman'; font-size:11pt">in receipt of</span><span style="font-family:'Times New Roman'; font-size:11pt"> cell</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">tissue </span><span style="font-family:'Times New Roman'; font-size:11pt">or organ transplantation </span><span style="font-family:'Times New Roman'; font-size:11pt">could have </span><span style="font-family:'Times New Roman'; font-size:11pt">contracted</span><span style="font-family:'Times New Roman'; font-size:11pt"> vCJD. </span><span style="font-family:'Times New Roman'; font-size:11pt">Medical histories of patients with vCJD were review to identify where donation or transplantation may have occurred and a look-back was then carried out to trace the respective recipients or donors of the implicated tissues. A single patient has undergone liver transplantation prior to vCJD onset from a donor who died of causes unrelated to vCJD. This patient also received red cell transfusions from 103 blood donors who we had already been </span><span style="font-family:'Times New Roman'; font-size:11pt">traced as part of the T</span><span style="font-family:'Times New Roman'; font-size:11pt">MER (</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">vide supra</span><span style="font-family:'Times New Roman'; font-size:11pt">).</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The look-back traced 6 other donations made by the same donor: two kidneys, two cornea and two heart valves. There is no evidence that these patients have developed vCJD. </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In 2006 NHSBT started an evaluation study to screen tissue donors for vCJD.  The study was later extended to cover tissue donors from the SNBTS and eye donors from the Corneal Transplant Service.  Screening for vCJD was feasible on tissue donors because, unlike blood donations, small pieces of lymphoreticular tissue such as tonsil and spleen could be taken at the time of donation for analysis.  Although only trace amounts of prion are present in blood, beyond the limit of detection of routine tests, vCJD prion is known to accumulate in tonsil and spleen tissue prior to the onset of clinical disease.  The testing uses a very sensitive western blot technique developed by NHSBT using reagents supplied by Prionics AG, </span><span style="font-family:'Times New Roman'; font-size:11pt">Switzerland</span><span style="font-family:'Times New Roman'; font-size:11pt">; it is designed for tissue samples but is not suitable for high throughput screening</span><span style="font-family:'Times New Roman'; font-size:11pt">.  The tonsil study tested 24% of eligible donations for vCJD, whereas the splenic &amp; ocular study has tested 68% of eligible donors to date. Currently, approximately 180 tissue donations and 1350 eye donations are tested per annum, at a </span><span style="font-family:'Times New Roman'; font-size:11pt">current </span><span style="font-family:'Times New Roman'; font-size:11pt">cost of approximately £240,000</span><span style="font-family:'Times New Roman'; font-size:11pt">/year</span><span style="font-family:'Times New Roman'; font-size:11pt">.  None of the donations have tested positive for vCJD.  The total cost of the study since commencement in 2006 has been approximately £750,000.</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 18.7pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Population prevalence studies based on </span><span style="font-family:'Times New Roman'; font-size:11pt">immunohistochemical examination of </span><span style="font-family:'Times New Roman'; font-size:11pt">tonsil</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt">appendix samples suggest a degree of population carriage that is far higher than has been reflected in transfusion cases to date</span><span style="font-family:'Times New Roman'; font-size:11pt"> or indeed clinical vCJD cases currently</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">The prevalence of positivity in blood itself is not known.  </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Questions.</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Question 1: a</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">re policies governing who can donate blood and blood products, tissues and organs sufficiently evidenced based?  Is NHS Blood and Transplant (UK Blood Services) overly restrictive about who can donate, or should greater precaution be taken to further reduce risk?</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="20" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In respect of variant CJD risk, </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> policies governing donation of blood and blood products, tissues and organs are based on the best available evidence and are reviewed on an on-going basis by UK Blood Services Joint Professional Advisory Committee and SaBTO. Nevertheless, there is considerable uncertainty as to the magnitude of the risk and the effectiveness of risk reduction measures, particularly perhaps in respect of donor selection criteria. UK Blood Services have therefore tended to take a precautionary stance wherever possible.  The deferral of </span><span style="font-family:'Times New Roman'; font-size:11pt">donors of </span><span style="font-family:'Times New Roman'; font-size:11pt">blood and </span><span style="font-family:'Times New Roman'; font-size:11pt">tissue</span><span style="font-family:'Times New Roman'; font-size:11pt">s who themselves have received blood, </span><span style="font-family:'Times New Roman'; font-size:11pt">cell, </span><span style="font-family:'Times New Roman'; font-size:11pt">tissue or organ transplantation is based on a decision to act to prevent tertiary and higher order transmissions of vCJD and the potential prolongation of the outbreak in the United Kingdom through this route.  The UK Blood Services sustained a 4 – 5% loss of donors during the implementation of this precautionary measure but blood donor rates have since stabilised and are currently adequate</span><span style="font-family:'Times New Roman'; font-size:11pt"> to meet the falling demand</span><span style="font-family:'Times New Roman'; font-size:11pt">.  For some cells such as haematopoietic stem cells and solid organs</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the degree of immunological matching required along with the shortfall in suitable donors and the life saving nature of the transplant procedure mean that in the judgement of SaBTO the risk</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> of the recipient contracting vCJD are outweighed by the risk that they will die from their underlying condition without treatment.  Although other countries exclude those of us who have lived in the </span><span style="font-family:'Times New Roman'; font-size:11pt">United Kingdom</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">for defined periods </span><span style="font-family:'Times New Roman'; font-size:11pt">from donating blood, clearly this would not be a sustainable policy within the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> itself.  Unfortunately there are no clear risk factors on which to base a </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> selective deferral process for blood donors.  </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 18.7pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="21" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Question 2: i</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">s the government and its Scientific Advisory structure sufficiently responsive to the threat posed by emerging diseases being transmitted through blood and blood products, tissues and organs?</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="22" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In respect of vCJD, the risk assessment and measures taken to ameliorate risk of transmission have been under almost continuous review since the mid 1990s, when the disease was first discussed by a variety of UK Blood Service internal committees and by MSBTO and its successor SaBTO (see separate submission). Indeed, the meeting which resulted in the setting up of the joint TMER study between NCJDRSU and the blood services took place in April 1996, before the first cases of vCJD had been reported in medical journals.</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="23" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">23. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Question 3: i</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">s the threat of ongoing transmission of vCJD through blood and the blood supply being adequately mitigated?</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 56.1pt; text-align:justify; text-indent:-18.7pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">24. </span><span style="font-family:'Times New Roman'; font-size:11pt">It is difficult to answer this question with certainty because of the </span><span style="font-family:'Times New Roman'; font-size:11pt">potentially </span><span style="font-family:'Times New Roman'; font-size:11pt">very long duration of sub-clinical infection in individuals affected with prion diseases.  On the positive side it can be noted that there has been no evidence of transmission of vCJD by blood trans</span><span style="font-family:'Times New Roman'; font-size:11pt">fusion</span><span style="font-family:'Times New Roman'; font-size:11pt"> since the introduction of universal leucodepletion in 1999.  On the other hand the prevalence of sub-clinical infection is estimated to be 1 in 2000 in the general population, the level of infectivity in the peripheral blood is unknown and the level of susceptibility of infected individuals to develop clinical disease in the longer term is unclear.  Therefore it would be premature to consider that there is no threat of ongoing transmission through blood components, tissues, cells and organs.  Plasma for manufacture of pharmaceutical agents is sourced outwith the </span><span style="font-family:'Times New Roman'; font-size:11pt">United Kingdom</span><span style="font-family:'Times New Roman'; font-size:11pt"> and therefore poses minimal risk.  UK Blood Services and SaBTO continue to review proposed new vCJD risk mitigation measures.  There are none of clear superior utility available at present.</span></p><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 18.7pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="25" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">UK Blood Services have taken a structured approach to vCJD risk since the outset. As well as implementing all policies recommended by SaBTO, we have established an infrastructure to consider donor selection, prion screening and removal, other manufacturing steps to reduce plasma content and donor exposure, and to drive down blood usage.  We have also invested </span><span style="font-family:'Times New Roman'; font-size:11pt">around £3m </span><span style="font-family:'Times New Roman'; font-size:11pt">in Research &amp; Development to develop and assess methods for both prion reduction in blood components and blood tests for prion screening. </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="26" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">UK Blood Services, through their</span><span style="font-family:'Times New Roman'; font-size:11pt"> Prion Working Group, has worked with manufacturers </span><span style="font-family:'Times New Roman'; font-size:11pt">since 2005 </span><span style="font-family:'Times New Roman'; font-size:11pt">to evaluate </span><span style="font-family:'Times New Roman'; font-size:11pt">new </span><span style="font-family:'Times New Roman'; font-size:11pt">commercial </span><span style="font-family:'Times New Roman'; font-size:11pt">filters specifically designed to remove infectious prions from red cells for transfusion.   </span><span style="font-family:'Times New Roman'; font-size:11pt">We commissioned and funded an independent evaluation of efficacy </span><span style="font-family:'Times New Roman'; font-size:11pt">(performed by the Health Protection Agency), of a CE marked filter (P-Capt, Macopharma) </span><span style="font-family:'Times New Roman'; font-size:11pt">in removing prions </span><span style="font-family:'Times New Roman'; font-size:11pt">and conducted a clinical </span><span style="font-family:'Times New Roman'; font-size:11pt">safety trial </span><span style="font-family:'Times New Roman'; font-size:11pt">of prion-filtered blood in 600 patients </span><span style="font-family:'Times New Roman'; font-size:11pt">between 2007 and </span><span style="font-family:'Times New Roman'; font-size:11pt">2011, at a total cost of £5.</span><span style="font-family:'Times New Roman'; font-size:11pt">22M.  Data from these studies were provided to SaBTO to inform their recommendations on the use of such filters.   </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 18.7pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="24" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Question 4: w</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">hat are the strengths and weaknesses of NHS Blood and Transplant strategy “taking normal transplantation to 2020”?  What further changes can be made to safety and increase the supply of blood and blood products, tissues and organs?</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="27" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">NHSBT</span><span style="font-family:'Times New Roman'; font-size:11pt"> will address this question</span><span style="font-family:'Times New Roman'; font-size:11pt"> in a separate submission</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="25" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Question 5: w</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">hat lessons can be learnt from the screening and donation practices of other countries?  </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="28" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">With respect to the development of a peripheral blood assay for vCJD, a number of significant challenges present themselves. Unlike microbiological agents such as bacteria and viruses the prion agent does not appear to elicit an immune response or have associated unique nucleic acid, therefore standard serological and PCR-based methods cannot </span><span style="font-family:'Times New Roman'; font-size:11pt">be used to </span><span style="font-family:'Times New Roman'; font-size:11pt">detect the infectious agent. </span><span style="font-family:'Times New Roman'; font-size:11pt">A variety of approaches have been used to differentiate the abnormal from the normal conformer of prion protein including differential resistance to proteinase-K </span><span style="font-family:'Times New Roman'; font-size:11pt">(PK) </span><span style="font-family:'Times New Roman'; font-size:11pt">digestion, epitope masking / unmasking, antibodies or other ligands</span><span style="font-family:'Times New Roman'; font-size:11pt"> specific to the abnormal conformer of prion protein (PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">TSE</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">, and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">in vitro</span><span style="font-family:'Times New Roman'; font-size:11pt"> amplification. </span><span style="font-family:'Times New Roman'; font-size:11pt">The majority of these approaches have not proved successful in achieving the level of sensitivity likely to be required to detect PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">TSE </span><span style="font-family:'Times New Roman'; font-size:11pt">in the peripheral blood of patients with sub-clinical vCJD infection and have been abandoned either on scientific or commercial grounds.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Three approaches are still under investigation / development: the MRC Prion Unit assay discussed by Professor Collinge in his submission and testi</span><span style="font-family:'Times New Roman'; font-size:11pt">mony to the Committee; the Quaking-Induced Conversion (QuIC)</span><span style="font-family:'Times New Roman'; font-size:11pt"> assay under development by NHSBT and also by Prionics (a Swiss company); the </span><span style="font-family:'Times New Roman'; font-size:11pt">Protein Misfolding Cyclic Amplification (</span><span style="font-family:'Times New Roman'; font-size:11pt">PMCA</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> assay under development by SNBTS, NCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">R</span><span style="font-family:'Times New Roman'; font-size:11pt">SU and EFS (the French Blood Transf</span><span style="font-family:'Times New Roman'; font-size:11pt">usion Service). Of these, the QuIC</span><span style="font-family:'Times New Roman'; font-size:11pt"> and PMCA assays are amplification assays and are very time consuming and labour intensive and therefore would not be suitable for a blood donor screening assay but could be used as confirmatory assay</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> (</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">vide infra</span><span style="font-family:'Times New Roman'; font-size:11pt">). </span><span style="font-family:'Times New Roman'; font-size:11pt">The status of these assays has been kept under review by the UK Blood Services Prion Working Group </span><span style="font-family:'Times New Roman'; font-size:11pt">which also has representatives from the Irish, Dutch and French Blood Services</span><span style="font-family:'Times New Roman'; font-size:11pt">. At this point, no assay is available ‘off-the-shelf’ which could be applied to the</span><span style="font-family:'Times New Roman'; font-size:11pt"> routine testing of blood donors (</span><span style="font-family:'Times New Roman'; font-size:11pt">&gt;</span><span style="font-family:'Times New Roman'; font-size:11pt">75</span><span style="font-family:'Times New Roman'; font-size:11pt">00 blood donations </span><span style="font-family:'Times New Roman'; font-size:11pt">per</span><span style="font-family:'Times New Roman'; font-size:11pt"> da</span><span style="font-family:'Times New Roman'; font-size:11pt">y in the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">.  </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="29" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In evaluating an assay for donor screening there are a number of fundamental issues which need to be taken into consideration</span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="30" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The first is the sensitivity of the assay </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">i.e.</span><span style="font-family:'Times New Roman'; font-size:11pt"> its ability to detect the agent when present. If we assume that the  level of infectivity in human blood is around 5</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">ID / 500ml (0.01ID/ml) and that the ratio of infectivity to PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">TSE </span><span style="font-family:'Times New Roman'; font-size:11pt">is similar to that seen in animal  models, </span><span style="font-family:'Times New Roman'; font-size:11pt">we are trying to detect as little</span><span style="font-family:'Times New Roman'; font-size:11pt"> as </span><span style="font-family:'Times New Roman'; font-size:11pt">0.1fg PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">TSE </span><span style="font-family:'Times New Roman'; font-size:11pt">/ ml in the context of 100ng / ml of </span><span style="font-family:'Times New Roman'; font-size:11pt">the normal prion protein - </span><span style="font-family:'Times New Roman'; font-size:11pt">PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">C </span><span style="font-family:'Times New Roman'; font-size:11pt">(a million-fold excess). Fractionation studies on brain homogenates have suggested that following PK-digestion particles in the size range 300-600kDa are associated with the highest specific infectivity, suggesting that a PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">TSE </span><span style="font-family:'Times New Roman'; font-size:11pt">oligomer of 14-28 molecules might </span><span style="font-family:'Times New Roman'; font-size:11pt">equate to</span><span style="font-family:'Times New Roman'; font-size:11pt">1ID. In addition the contribution of PK-sensitive form of PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">TSE </span><span style="font-family:'Times New Roman'; font-size:11pt">is uncertain and the exact relationship between PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">TSE </span><span style="font-family:'Times New Roman'; font-size:11pt">and infectivity is complex. Finally, if the infectious agent is quantal in nature, there will only be one ID in 100ml of blood and a sample of 10ml (say) would only have a 10% chance of containing such an ID. These estimates are not intended to be definitive, only illustrative of the challenges faced by vCJD peripheral blood assay developers.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="31" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The second issue is specificity of the assay </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">i.e.</span><span style="font-family:'Times New Roman'; font-size:11pt"> its ability to detect the absence of the agent. The analytical specificity of the assay its dependent on its ability not to ‘mistake’ the normal conformer of PrP (PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">C</span><span style="font-family:'Times New Roman'; font-size:11pt">) or other molecules for the abnormal conformer (PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">TSE</span><span style="font-family:'Times New Roman'; font-size:11pt">). However, in practice the specificity of the assay will depend upon the population within which it is deployed as illustrated in Figure 1 below. Hence (for example) if we assume the prevalence of subclinical vCJD in the UK to be 1/2000 of the general population and were to screen say 2,000,000 donors per annum, and if we had a hypothetical screening test with 99% sensitivity and specificity, then we would detect 999 true positives </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">per annum</span><span style="font-family:'Times New Roman'; font-size:11pt"> through a reaction in the screening assay, we would fail to identify one true positive whose sample would not show a reaction in the test, correctly identify a very large number of true negatives, but falsely identify as positive just short of 20,000 people each year whose blood would show a reaction in the test, even though they were not truly infected. In the absence of a confirmatory assay,all of these people would have to be contacted and informed of their reactive test result as it would be impossible to differentiate the true positives and the false positives.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify"><img src="data:image/png;base64,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" width="636" height="420" alt="" /></p><ol start="32" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The third issue is the methodology for evaluation of the assay. </span><span style="font-family:'Times New Roman'; font-size:11pt">Most blood screening assays are validated on large numbers of samples from individuals with the infection in question.  This is not possible in the case of vCJD because of the relatively small numbers of patients and the fact that it is not ethically acceptable to remove large volumes of blood from these affected individuals, purely to be used for test evaluaion. Hence, evaluation has been carried out through a phased approach using spiked brain and spleen homogenates and endogenously infected blood from animals in pre-clinical and clinical phases of prion diseases, prior to accessing the very few samples from patients with variant CJD and other forms of CJD as described by colleagues at NIBSC in their submission to the Committee.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">UK Blood Services have also established a vCJD Test Assessment Facility </span><span style="font-family:'Times New Roman'; font-size:11pt">for evaluation of candidate assays </span><span style="font-family:'Times New Roman'; font-size:11pt">at a cost of £3.12m which includes </span><span style="font-family:'Times New Roman'; font-size:11pt">5000 </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and 5000</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">US</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">aliquotted </span><span style="font-family:'Times New Roman'; font-size:11pt">blood donations </span><span style="font-family:'Times New Roman'; font-size:11pt">(the latter assumed negative) </span><span style="font-family:'Times New Roman'; font-size:11pt">which are anonymized, unlinked and unimputable to their donors. </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 18.7pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="33" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The fourth issue is the management of those individuals whose blood shows a reaction in an assay. Unlike a population prevalence study, in which test samples can be anonymised, unlinked and un-imputable to their origin, Blood, Cell, Tissue and Organ Services must retain linkage between donor(s) and recipient(s). </span><span style="font-family:'Times New Roman'; font-size:11pt">During routine current screening of blood, cell, tissue and organ donors for infections such as HIV, HBC and HCV, samples which are initially reactive are retested using the same assay and if repeat reactive are withdrawn from the system and sent for repeat testing using a variety of other assays based on other principles (termed confirmatory assays). A donor will only be informed of a positive test result if they are confirmed to have the infection in question. This allows Blood Services to use initial screening assays of high sensitivity, but only inform and exclude those donors who are genuinely infected. </span><span style="font-family:'Times New Roman'; font-size:11pt">A donor who tests reactive on a vCJD screening assay will </span><span style="font-family:'Times New Roman'; font-size:11pt">similarly need to </span><span style="font-family:'Times New Roman'; font-size:11pt">be excluded from further donation in order to safeguard public health and will have to be informed of the test result.  Hence, the </span><span style="font-family:'Times New Roman'; font-size:11pt">need to differentiate between </span><span style="font-family:'Times New Roman'; font-size:11pt">the true and false positives through the use of confirmatory assays is </span><span style="font-family:'Times New Roman'; font-size:11pt">also critical in this</span><span style="font-family:'Times New Roman'; font-size:11pt"> context. Moreover, the implications of </span><span style="font-family:'Times New Roman'; font-size:11pt">repeat reactivity </span><span style="font-family:'Times New Roman'; font-size:11pt">in the context </span><span style="font-family:'Times New Roman'; font-size:11pt">of PrP</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">TSE </span><span style="font-family:'Times New Roman'; font-size:11pt">detection </span><span style="font-family:'Times New Roman'; font-size:11pt">is un</span><span style="font-family:'Times New Roman'; font-size:11pt">certain – it is unknown, for example, whether such an individual would ever </span><span style="font-family:'Times New Roman'; font-size:11pt">progress to </span><span style="font-family:'Times New Roman'; font-size:11pt">develop clinical variant CJD. It is likely that informing donors of repeat reactive results will have an adverse psychological and social impact on at least some people and may impact more widely on donor recruitment and retention. Focus group studies carried out by UK Blood Services suggest that most donors would accept vCJD screening only if there were confidence in the testing strategy and the existence of reliable confirmatory assays.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="34" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:200%; margin:0pt 0pt 0pt 55.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In summary, the following criteria will need to be addressed prior to implementation of vCJD screening of blood, cell, tissue and organ donors in the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> (or indeed elsewhere): </span></li><ol type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 66.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">a </span><span style="font-family:'Times New Roman'; font-size:11pt">need for assays with a very high degree of overall sensitivity; </span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 67.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">a high degree of first pass specificity in the screening assay; </span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 66.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">a standardised operationalisable assay platform to allow reproducible and affordable screening</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">with a result available in &lt;24 hours </span><span style="font-family:'Times New Roman'; font-size:11pt">(UK Blood Services test around 7,500 samples per day)</span><span style="font-family:'Times New Roman'; font-size:11pt">; </span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 67.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">an assay which is CE marked and conforms to the European Common Technical Specification which allows it to be manufactured and marketed.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 66.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">a confirmatory assay strategy; </span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 65.41pt; padding-left:6.59pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">a large scale population prevalence study</span><span style="font-family:'Times New Roman'; font-size:11pt"> using blood samples</span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 67.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">a well considered approach to engagement with the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> donor groups</span><span style="font-family:'Times New Roman'; font-size:11pt"> regarding communication of positive results</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol></ol><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:200%; margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Declaration of Interests.</span></p><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">This report was pr</span><span style="font-family:'Times New Roman'; font-size:11pt">epared</span><span style="font-family:'Times New Roman'; font-size:11pt"> by Marc Turner, Chair of UK Blood Services Prion Working Group, Professor of Cellular Therapy at the </span><span style="font-family:'Times New Roman'; font-size:11pt">University</span><span style="font-family:'Times New Roman'; font-size:11pt"> of </span><span style="font-family:'Times New Roman'; font-size:11pt">Edinburgh</span><span style="font-family:'Times New Roman'; font-size:11pt"> and Medical Director of the Scottish National Blood Transfusion Service. Marc Turner is also a Non-Executive Director of Roslin Cells Ltd (pro bono) and of the Cell Therapy Catapult and was an appointed member of the Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) from its inception until November 2013.</span></p><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:200%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">January 2014</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAmCAYAAADui0oEAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAAAYSURBVChTY2BAAv9h7FEGMCTICwRwEAIACKAj3QiVg1QAAAAASUVORK5CYII=" width="2" height="38" alt="" style="margin-left:112.8pt; margin-top:634.4pt; position:absolute; z-index:2" /><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAIAAAAmCAYAAADui0oEAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAAAYSURBVChTY2BAAv9h7FEGMCTICwRwEAIACKAj3QiVg1QAAAAASUVORK5CYII=" width="2" height="38" alt="" style="margin-left:112.8pt; margin-top:634.4pt; position:absolute; z-index:1" /></p><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p></div></body></html>